This week on Tech Can’t Save Us, host Paul David is joined by Dr. Joel Braunstein, co-founder, CEO, and president of C2N Diagnostics, a pioneering biotech company transforming the way we diagnose Alzheimer’s disease.

They explore how C2N is advancing blood-based diagnostic tools, most notably the Precivity AD test that delivers accuracy comparable to PET scans and spinal taps, but in a simpler, less invasive format. Joel shares how these innovations are reducing misdiagnosis rates, empowering clinicians, and providing families with clarity during some of their most difficult moments.

Joel reflects on his journey from cardiologist at Johns Hopkins to biotech founder, the curiosity and persistence that drive his work, and the importance of balancing rapid innovation with clinical rigor. He also shares personal insights, quickfire takes on tech innovation, and the philosophies that keep him grounded.

Find more about C2N Diagnostics here: https://www.c2n.com

Follow Dr.Braustein: https://www.linkedin.com/in/joel-braunstein-md-9456611/